Routine pelvic lymphadenectomy in apparently early stage endometrial cancer

L. D. Zuurendonk, R. A. Smit, B. W J Mol, H. W H Feijen, J. de Graaff, D. Sykora, K. A J de Winter, A. vd Wurff, M. P M L Snijders, R. F P M Kruitwagen

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Aims: Controversial issues with respect to the treatment of patients with endometrial cancer include indications for lymphadenectomy and adjuvant radiotherapy. Patient and methods: Between 1998 and 2004 all women with endometrial cancer stage I were included (n=335). They all underwent total abdominal hysterectomy and bilateral salpingo-oöphorectomy. Two hundred and thirty-seven women also had a pelvic lymphadenectomy. When pelvic lymphadenectomy was performed, radiotherapy was administered only to patients with lymph-node metastases. Otherwise, adjuvant radiotherapy was based on the presence of risk factors. Results: Eleven patients had lymph-node metastases. The overall absolute and relative survival-estimate at 5 years was 85.0 and 93.7%, respectively. Loco-regional recurrence was 8.5%. In the group with pelvic lymphadenectomy and negative lymph nodes these rates were 88.2, 93.9 and 5.6%, respectively. In 58 patients without any of the risk factors tumour grade III, deep myometrial invasion, or age ≥60 years, no lymph-node metastases were found. Conclusion: In patients with endometrial cancer FIGO stage I without risk-factors, a phenomenon which occurs in about 25% of patients with clinical stage I endometrial cancer, a lymphadenectomy can be omitted. In other patients, the debate regarding the optimal treatment will remain.

Original languageEnglish
Pages (from-to)450-454
Number of pages5
JournalEuropean Journal of Surgical Oncology
Issue number4
Publication statusPublished - 1 May 2006


  • Endometrial carcinoma
  • Lymph node excision
  • Lymphatic metastases
  • Survival rate

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this